Type 1 diabetes trial news: a company has begun dosing participants with an investigational oral therapy; the article outlines study plans and implications.
Key Takeaways
- Phase 2 randomized placebo-controlled trial will enroll about 34 adults on automated insulin delivery
- Primary endpoint is continuous glucose monitoring time-in-range, with HbA1c and insulin dose secondary
- Prior clinical studies reported about a 50% reduction in insulin resistance and improved glycemia